An Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Simufilam 100 Mg Tablets in Participants with Mild to Moderate Alzheimer's Disease
Latest Information Update: 25 May 2025
At a glance
- Drugs Simufilam (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Cassava Sciences
Most Recent Events
- 12 Dec 2024 Planned End Date changed from 15 Jul 2026 to 28 Mar 2025.
- 12 Dec 2024 Planned primary completion date changed from 15 Jul 2026 to 28 Mar 2025.
- 25 Nov 2024 Status changed from active, no longer recruiting to discontinued as per a Cassava Sciences media release.